Meeting
2017 Gastrointestinal Cancers Symposium
Phase 1b study with PEGylated human IL-10 (AM0010) with 5-FU and oxaliplatin (FOLFOX) in metastatic pancreatic adenocarcinoma (PDAC).
Authors
J. Randolph Hecht
David Geffen School of Medicine at UCLA, Los Angeles, CA
J. Randolph Hecht , Aung Naing , Gerald Falchook , Manish R. Patel , Jeffrey R. Infante , Raid Aljumaily , Deborah Jean Lee Wong , Karen A. Autio , Zev A. Wainberg , Milind M. Javle , Johanna C. Bendell , Shubham Pant , Peter Van Vlasselaer , Gail Linda Brown , Martin Oft , Kyriakos P. Papadopoulos
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Multidisciplinary Treatment
Citation
J Clin Oncol 35, 2017 (suppl 4S; abstract 399)
DOI
10.1200/JCO.2017.35.4_suppl.399
Abstract #
399
Poster Bd #
J5
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Overall survival of PEGylated pegilodecakin with 5-FU/LV and oxaliplatin (FOLFOX) in metastatic pancreatic adenocarcinoma (PDAC).
First Author: J. Randolph Hecht
Poster
2018 Gastrointestinal Cancers Symposium
Overall survival of PEGylated human IL-10 (AM0010) with 5-FU/LV and oxaliplatin (FOLFOX) in metastatic pancreatic adenocarcinoma (PDAC).
First Author: J. Randolph Hecht
Poster
2024 ASCO Gastrointestinal Cancers Symposium
De-escalation and dose density in real-world patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) who received FOLFIRINOX in the first line.
First Author: Syvart Dennen
Poster
2024 ASCO Gastrointestinal Cancers Symposium
A phase 1b/2 trial of pepinemab and avelumab as second line therapy for patients with metastatic pancreatic adenocarcinoma.
First Author: Bailey Hilty